Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma

Key Points

• This review aims to evaluate the effectiveness of an on-body injector (OBI) in delivering isatuximab for multiple myeloma.
• Analysis of the on-body injector's design and functionality
• Review of clinical workflows affected by the OBI
• Evaluation of patient experience improvements with OBI
• Potential reduction in clinical visit duration due to hands-free administration
• Decreased physical burden on healthcare providers during drug delivery
• Enhanced patient experience reported due to the small, hidden needle of the OBI